We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

So, assuming 2% growth, Gilead is slightly undervalued. In fact, Gilead appears valued for 0% growth. Actually, this may be a ...

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

Across the recent three months, 14 analysts have shared their insights on Gilead Sciences GILD, expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Gilead Sciences (GILD) is one of the stocks most ... While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to ...

Gilead Sciences has declared a quarterly dividend to stockholders on record at the close of business on March 14, 2025. (Reuters) Gilead Sciences, with a market capitalization of $143.8 billion ...

In this article, we are going to take a look at where Gilead Sciences Inc (NASDAQ:GILD) stands against other top stocks Wall Street is discussing. Bill Strazzullo, Bell Curve Trading chief market ...

Gilead (GILD) Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s injectable HIV-1 capsid inhibitor ...

Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of $120.00. The company’s shares closed yesterday at $114.43.

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ ... According to CNBC, buyers have devised a business model allowing them to import medicines through licensing ...